Yahoo Web Search

Search results

    • Tango terminates USP1 inhibitor programme

      Tango terminates USP1 inhibitor programme

      Clinical Trials Arena via Yahoo Finance· 2 hours ago

      The company’s market cap stands at $757.5m. Tango also planned to evaluate its therapy in combination with AstraZeneca’s and Merck & Co’s poly-ADP ribose...